Roth Capital Forecasts Reduced Earnings for Sanuwave Health

Key Points

• Roth Capital revised its Q3 2025 EPS estimates for Sanuwave Health, lowering the expected earnings from $0.65 to $0.61 per share.
• Sanuwave Health currently holds a Buy rating from Roth Capital, which has set a target price of $53.00 for the stock.
• Following recent reports, Sanuwave has received mixed ratings from analysts, with one strong buy, two buys, and one sell, resulting in an average rating of "Moderate Buy".

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Stock analysts at Roth Capital cut their Q3 2025 EPS estimates for shares of Sanuwave Health in a report released on Monday, October 6th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings of $0.61 per share for the quarter, down from their previous estimate of $0.65. Roth Capital currently has a "Buy" rating and a $53.00 target price on the stock.

SNWV has been the subject of a number of other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Sanuwave Health in a report on Saturday, September 27th. Wall Street Zen upgraded shares of Sanuwave Health from a "hold" rating to a "buy" rating in a research report on Friday, October 3rd. Northland Capmk raised shares of Sanuwave Health to a "strong-buy" rating in a report on Wednesday, September 3rd. Finally, Northland Securities started coverage on shares of Sanuwave Health in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $54.00.

Sanuwave Health Price Performance

Sanuwave Health stock opened at $32.01 on Wednesday. The business has a 50 day simple moving average of $37.78 and a 200 day simple moving average of $33.88. The company has a market capitalization of $274.33 million, a PE ratio of -3.88 and a beta of 1.33. Sanuwave Health has a one year low of $5.63 and a one year high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Investors Weigh In On Sanuwave Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc acquired a new stake in Sanuwave Health during the 2nd quarter worth $26,000. BNP Paribas Financial Markets acquired a new position in Sanuwave Health in the second quarter valued at about $46,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Sanuwave Health during the 1st quarter worth about $47,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Sanuwave Health during the second quarter valued at approximately $52,000. Finally, New York State Common Retirement Fund acquired a new stake in Sanuwave Health in the second quarter worth $102,000. 42.53% of the stock is owned by institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.